Maged Ghaly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maged Ghaly has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Zaker Rana
Department of Radiation Medicine, Northwell Health, Lake Success, NY, USA
6 shared publications- Emile Gogineni
Department of Radiation Oncology, The James Cancer Hospital/Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA
5 shared publications Douglas Frank
Department of Otolaryngology – Head and Neck Surgery Northwell Health Cancer Institute Lake Success New York USA
4 shared publicationsNagashree Seetharamu
Northwell Health
4 shared publications- Anuradha Bapsi Chakravarthy
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
3 shared publications - Barbara Burtness
Yale School of Medicine and Yale Cancer Center New Haven Connecticut USA
3 shared publications
Latest Publications
- 14 October 2026
- Published by Wiley in Head & Neck
Stereotactic Body Radiation Therapy for Management of Locally Advanced Periorbital Tumors: Efficacy and Toxicity Profile
Background: The management of locally advanced periorbital skin tumors with orbital invasion is challenging. Orbital exenteration historically provides reliable local control but causes major functional and cosmetic morbidity. We evaluated stereotactic body radiation therapy (SBRT) as an eye‐sparing alternative, focusing on local control, vision preservation, and toxicity. Methods: This retrospective series includes 26 consecutive patients with locally advanced periorbital tumors treated prospectively with SBRT. Tumors involved the canthi (zones III–IV) in 20 patients, with multi‐zone involvement in 18 and complete periorbital skin invasion (zone V) in 4. Eighteen tumors violated the orbital septum; anterior orbital invasion was observed in 16, and middle orbital invasion in 14. Extraconal violation occurred in 16 patients, and intraconal invasion in 15 patients. All patients were presented with intact ipsilateral vision at baseline. SBRT was delivered using VMAT/IMRT with a simultaneous integrated boost of 35–40 Gy to GTV and 25 Gy to CTV + 2 mm over five biweekly fractions. Optic apparatus constraints included Orbit PRV and Optic N PRV maximum point ≤ 30 Gy and mean ≤ 20 Gy; Lacrimal gland mean < 26 Gy when feasible. OAR constraints were based on institutional treatment directives supported by AAPM TG‐101, QUANTEC, and Emami et al. 50% received systemic therapy, including immunotherapy, targeted therapy, or chemotherapy, with some receiving combined approaches. Local and regional control and toxicities (CTCAE v5.0) were recorded; statistical analysis was primarily descriptive. Kaplan–Meier methodology was used to estimate local control and overall survival. Given the limited cohort size and heterogeneous tumor histologies, no formal comparative statistical testing was performed. Results: Twenty‐four patients presented with primary cutaneous tumors and 2 had non‐cutaneous histologies (solitary fibrous tumor and metastatic breast carcinoma). SBRT was delivered as definitive therapy in 19 patients and as adjuvant therapy in 7. Median planning target volumes (PTVs) were 45 cc (PTV25) and 9 cc (PTV35–40 Gy), with corresponding median D90 values of 29 and 34/42 Gy, respectively. At a median follow‐up of 18 months (range 4–50 months), all patients retained intact vision. Twenty‐one patients achieved complete response, one had stable disease, and three experienced locoregional recurrences—one cavernous sinus failure and two local‐regional relapses. Acute toxicities were predominantly mild, including Grade 1 dermatitis ( n = 15), conjunctivitis ( n = 8), diplopia ( n = 7), orbital pain ( n = 1), and hyperpigmentation ( n = 2). Grade 2 dermatitis occurred in 6 patients, while Grade 3 dermatitis was rare ( n = 2), both requiring reconstructive grafting. On follow‐up, late effects included blurred vision ( n = 6), epiphora ( n = 3), orbital pain ( n = 2), and cataract progression ( n = 2), with isolated cases of trichiasis ( n = 1) and post‐surgical ptosis ( n = 2). One of four patients with zone V involvement developed a chronic corneal ulcer requiring surgical management. Conclusion: SBRT with a simultaneous integrated boost is a feasible eye‐sparing option for selected patients with locally advanced periorbital tumors, providing high rates of local control and vision preservation with acceptable toxicity. Prospective evaluation and longer follow‐up are warranted.
- 14 October 2026
- Published by Wiley in Head & Neck
Stereotactic Body Radiation Therapy for Management of Locally Advanced Periorbital Tumors: Efficacy and Toxicity Profile
Background: The management of locally advanced periorbital skin tumors with orbital invasion is challenging. Orbital exenteration historically provides reliable local control but causes major functional and cosmetic morbidity. We evaluated stereotactic body radiation therapy (SBRT) as an eye‐sparing alternative, focusing on local control, vision preservation, and toxicity. Methods: This retrospective series includes 26 consecutive patients with locally advanced periorbital tumors treated prospectively with SBRT. Tumors involved the canthi (zones III–IV) in 20 patients, with multi‐zone involvement in 18 and complete periorbital skin invasion (zone V) in 4. Eighteen tumors violated the orbital septum; anterior orbital invasion was observed in 16, and middle orbital invasion in 14. Extraconal violation occurred in 16 patients, and intraconal invasion in 15 patients. All patients were presented with intact ipsilateral vision at baseline. SBRT was delivered using VMAT/IMRT with a simultaneous integrated boost of 35–40 Gy to GTV and 25 Gy to CTV + 2 mm over five biweekly fractions. Optic apparatus constraints included Orbit PRV and Optic N PRV maximum point ≤ 30 Gy and mean ≤ 20 Gy; Lacrimal gland mean < 26 Gy when feasible. OAR constraints were based on institutional treatment directives supported by AAPM TG‐101, QUANTEC, and Emami et al. 50% received systemic therapy, including immunotherapy, targeted therapy, or chemotherapy, with some receiving combined approaches. Local and regional control and toxicities (CTCAE v5.0) were recorded; statistical analysis was primarily descriptive. Kaplan–Meier methodology was used to estimate local control and overall survival. Given the limited cohort size and heterogeneous tumor histologies, no formal comparative statistical testing was performed. Results: Twenty‐four patients presented with primary cutaneous tumors and 2 had non‐cutaneous histologies (solitary fibrous tumor and metastatic breast carcinoma). SBRT was delivered as definitive therapy in 19 patients and as adjuvant therapy in 7. Median planning target volumes (PTVs) were 45 cc (PTV25) and 9 cc (PTV35–40 Gy), with corresponding median D90 values of 29 and 34/42 Gy, respectively. At a median follow‐up of 18 months (range 4–50 months), all patients retained intact vision. Twenty‐one patients achieved complete response, one had stable disease, and three experienced locoregional recurrences—one cavernous sinus failure and two local‐regional relapses. Acute toxicities were predominantly mild, including Grade 1 dermatitis ( n = 15), conjunctivitis ( n = 8), diplopia ( n = 7), orbital pain ( n = 1), and hyperpigmentation ( n = 2). Grade 2 dermatitis occurred in 6 patients, while Grade 3 dermatitis was rare ( n = 2), both requiring reconstructive grafting. On follow‐up, late effects included blurred vision ( n = 6), epiphora ( n = 3), orbital pain ( n = 2), and cataract progression ( n = 2), with isolated cases of trichiasis ( n = 1) and post‐surgical ptosis ( n = 2). One of four patients with zone V involvement developed a chronic corneal ulcer requiring surgical management. Conclusion: SBRT with a simultaneous integrated boost is a feasible eye‐sparing option for selected patients with locally advanced periorbital tumors, providing high rates of local control and vision preservation with acceptable toxicity. Prospective evaluation and longer follow‐up are warranted.
- Open Access
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1898567
Local control after stereotactic radiation for thyroid cancer: a histology risk-stratified analysis
Purpose/Objective(s): Recurrent and metastatic non-anaplastic thyroid cancer has traditionally been considered relatively radioresistant. We evaluated whether anatomic site or histology risk group better predicts local control (LC) following stereotactic radiation therapy (SBRT/SRS). Materials/Methods: We retrospectively reviewed 32 patients with 66 treated lesions (42 skeletal, 24 non-skeletal) treated between 2012 and 2025. Histology was dichotomized into low-risk (papillary, follicular, medullary, Hürthle cell; n=61) and high-risk (poorly differentiated and squamous cell carcinoma; n=5). BED 10 was calculated using α/β = 10 Gy. LC was defined per RECIST 1.1. Kaplan–Meier and log-rank tests were used. Intra-patient correlation was addressed via generalized estimating equations (GEE) and Cox shared frailty models. A multivariable GEE model included histology risk, site, BED 10 , PTV volume, prior surgery, and age. Results: Median follow-up was 15.0 months. Six local failures occurred (crude LC 90.9%); 1- and 2-year LC were 96.5% and 87.1%. Histology risk was the dominant determinant: low-risk histology achieved 95.1% crude LC versus 40.0% for high-risk (log-rank p=0.002). In multivariable GEE analysis, low-risk histology was independently associated with LC (OR 158.0, 95% CI 1.72–14,479.7; p=0.028), whereas skeletal site was not (OR 1.07, 95% CI 0.02–51.8; p=0.974). BED 10 was not associated with LC after adjustment (p=0.752). Skeletal and non-skeletal LC were similar after histology stratification (95.0% vs 95.2% among low-risk). Treatment was well tolerated; no Grade ≥3 radiation toxicity, myelopathy, or fractures occurred. Conclusion: In stereotactic radiation for metastatic non-anaplastic thyroid cancer, histology risk grouping—not anatomic site or dose escalation—is the dominant predictor of local control. These findings support histology-based risk stratification for SRT patient selection.
- 30 September 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1898567
Open AccessLocal control after stereotactic radiation for thyroid cancer: a histology risk-stratified analysis
Purpose/Objective(s): Recurrent and metastatic non-anaplastic thyroid cancer has traditionally been considered relatively radioresistant. We evaluated whether anatomic site or histology risk group better predicts local control (LC) following stereotactic radiation therapy (SBRT/SRS). Materials/Methods: We retrospectively reviewed 32 patients with 66 treated lesions (42 skeletal, 24 non-skeletal) treated between 2012 and 2025. Histology was dichotomized into low-risk (papillary, follicular, medullary, Hürthle cell; n=61) and high-risk (poorly differentiated and squamous cell carcinoma; n=5). BED 10 was calculated using α/β = 10 Gy. LC was defined per RECIST 1.1. Kaplan–Meier and log-rank tests were used. Intra-patient correlation was addressed via generalized estimating equations (GEE) and Cox shared frailty models. A multivariable GEE model included histology risk, site, BED 10 , PTV volume, prior surgery, and age. Results: Median follow-up was 15.0 months. Six local failures occurred (crude LC 90.9%); 1- and 2-year LC were 96.5% and 87.1%. Histology risk was the dominant determinant: low-risk histology achieved 95.1% crude LC versus 40.0% for high-risk (log-rank p=0.002). In multivariable GEE analysis, low-risk histology was independently associated with LC (OR 158.0, 95% CI 1.72–14,479.7; p=0.028), whereas skeletal site was not (OR 1.07, 95% CI 0.02–51.8; p=0.974). BED 10 was not associated with LC after adjustment (p=0.752). Skeletal and non-skeletal LC were similar after histology stratification (95.0% vs 95.2% among low-risk). Treatment was well tolerated; no Grade ≥3 radiation toxicity, myelopathy, or fractures occurred. Conclusion: In stereotactic radiation for metastatic non-anaplastic thyroid cancer, histology risk grouping—not anatomic site or dose escalation—is the dominant predictor of local control. These findings support histology-based risk stratification for SRT patient selection.
- 14 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Neoadjuvant chemotherapy and surgery versus surgery for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) ECOG-ACRIN EA3163
Purpose: Neoadjuvant chemotherapy for structure preservation (SP) in nasal and paranasal sinus squamous cell carcinoma (NPNSCC) has been described in single-institution but not randomized studies. EA3163 was a randomized study investigating whether cytoreductive neoadjuvant chemotherapy would improve SP or overall survival (OS). Patients and Methods: Patients with T3/T4a and select T4b NPNSCC requiring orbital or base of skull (BOS) resection were randomized to surgery (Arm A), versus surgery preceded by docetaxel/cisplatin x3 cycles (Arm B). Degree of anticipated SP (orbit and BOS) was required preoperatively and post-chemotherapy. SP was noted at surgery. Co-primary objectives were SP rate (orbit/BOS) and OS. 82 patients needed to be accrued for 81% power with 0.1 one-sided alpha using Fisher’s exact test for SP rate and 83% with 0.1 one-sided alpha using log-rank test for OS. Results: Among 23 evaluable patients, overall SP rate was 30%: 15% in Arm A (N=2/13, 95%CI: 1.9-45.4%), 50% in Arm B (N=5/10, 95%CI: 18.7-81.3%) (p=0.17). Among 18 patients with pathologic T3/T4a disease, overall SP rate was 39%: 18% in Arm A (N=2/11, 95%CI: 2.3-51.8%), 71% in Arm B (N=5/7, 95%CI: 29.0-96.3%) (p=0.049). Orbit and BOS-specific preservation rates were 38% (95%CI: 8.5-75.5%) vs 83% (95%CI: 35.9-99.6%), and 33% (95%CI: 9.9-65.1%) vs 67% (95%CI: 29.9-92.5%) in Arm A vs B, respectively. The most common grade ≥3 toxicities included mucositis, anemia, nausea and lymphopenia (all >10%). No grade 5 events were reported. Conclusions: These results support neoadjuvant chemotherapy as an effective intervention for SP in T3/T4a NPNSCC and deserve further evaluation.
- 14 April 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
Neoadjuvant chemotherapy and surgery versus surgery for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) ECOG-ACRIN EA3163
Purpose: Neoadjuvant chemotherapy for structure preservation (SP) in nasal and paranasal sinus squamous cell carcinoma (NPNSCC) has been described in single-institution but not randomized studies. EA3163 was a randomized study investigating whether cytoreductive neoadjuvant chemotherapy would improve SP or overall survival (OS). Patients and Methods: Patients with T3/T4a and select T4b NPNSCC requiring orbital or base of skull (BOS) resection were randomized to surgery (Arm A), versus surgery preceded by docetaxel/cisplatin x3 cycles (Arm B). Degree of anticipated SP (orbit and BOS) was required preoperatively and post-chemotherapy. SP was noted at surgery. Co-primary objectives were SP rate (orbit/BOS) and OS. 82 patients needed to be accrued for 81% power with 0.1 one-sided alpha using Fisher’s exact test for SP rate and 83% with 0.1 one-sided alpha using log-rank test for OS. Results: Among 23 evaluable patients, overall SP rate was 30%: 15% in Arm A (N=2/13, 95%CI: 1.9-45.4%), 50% in Arm B (N=5/10, 95%CI: 18.7-81.3%) (p=0.17). Among 18 patients with pathologic T3/T4a disease, overall SP rate was 39%: 18% in Arm A (N=2/11, 95%CI: 2.3-51.8%), 71% in Arm B (N=5/7, 95%CI: 29.0-96.3%) (p=0.049). Orbit and BOS-specific preservation rates were 38% (95%CI: 8.5-75.5%) vs 83% (95%CI: 35.9-99.6%), and 33% (95%CI: 9.9-65.1%) vs 67% (95%CI: 29.9-92.5%) in Arm A vs B, respectively. The most common grade ≥3 toxicities included mucositis, anemia, nausea and lymphopenia (all >10%). No grade 5 events were reported. Conclusions: These results support neoadjuvant chemotherapy as an effective intervention for SP in T3/T4a NPNSCC and deserve further evaluation.
- 11 November 2023
- Published by Wiley in Head & Neck
- Vol. 46 (2) , 262-268
Clinical predictors of premature radiotherapy terminations in senior adults with oral cavity and laryngeal carcinoma
Introduction: The underlying factors that contribute to early radiotherapy (RT) termination are understudied, especially in the era of hypofractionated treatment regimens. In this retrospective investigation, we examined the characteristics and causes of premature RT terminations in senior adults (>70 years old) with oral cavity (OC) and laryngeal carcinomas.Methods: Hundred and eighty-eight patients treated with RT +/- systemic therapy for OC and laryngeal cancer from 2017 to 2022 were identified. Premature termination was defined as completion of less than 95% of the prescribed RT. Logistic regression analysis was performed to examine factors predictive of premature termination, and survival was determined using the Kaplan-Meier method.Results: Twenty patients (10.6%) experienced premature RT terminations. On regression analysis, ECOG score at initiation of RT was the only covariate studied to be independently associated with premature termination (OR 2.00, 95%CI: [1.21, 3.30], p = 0.007). Three-year overall survival (49.1% vs. 77.3%) was significantly reduced in the termination cohort (p < 0.0001).Conclusions: This analysis demonstrated over 1 in 10 patients had premature RT termination, which prognosticated inferior survival outcomes. Poor performance status may highlight patients at risk for premature termination and thus identify good candidates for hypofractionated protocols.
- 11 November 2023
- Published by Wiley in Head & Neck
- Vol. 46 (2) , 262-268
Clinical predictors of premature radiotherapy terminations in senior adults with oral cavity and laryngeal carcinoma
Introduction: The underlying factors that contribute to early radiotherapy (RT) termination are understudied, especially in the era of hypofractionated treatment regimens. In this retrospective investigation, we examined the characteristics and causes of premature RT terminations in senior adults (>70 years old) with oral cavity (OC) and laryngeal carcinomas.Methods: Hundred and eighty-eight patients treated with RT +/- systemic therapy for OC and laryngeal cancer from 2017 to 2022 were identified. Premature termination was defined as completion of less than 95% of the prescribed RT. Logistic regression analysis was performed to examine factors predictive of premature termination, and survival was determined using the Kaplan-Meier method.Results: Twenty patients (10.6%) experienced premature RT terminations. On regression analysis, ECOG score at initiation of RT was the only covariate studied to be independently associated with premature termination (OR 2.00, 95%CI: [1.21, 3.30], p = 0.007). Three-year overall survival (49.1% vs. 77.3%) was significantly reduced in the termination cohort (p < 0.0001).Conclusions: This analysis demonstrated over 1 in 10 patients had premature RT termination, which prognosticated inferior survival outcomes. Poor performance status may highlight patients at risk for premature termination and thus identify good candidates for hypofractionated protocols.
- 1 December 2022
- Published by S. Karger AG in ORL
- Vol. 85 (1) , 28-35
Osteoradionecrosis versus Cancer Recurrence: An Unresolved Clinical Dilemma
Introduction: Osteoradionecrosis is a rare and debilitating risk of definitive chemoradiotherapy for head and neck squamous cell carcinoma. It is difficult to distinguish between osteoradionecrosis and recurrent or progressive disease, as clinical and radiologic features may be similar. Our aim was to compare the clinical presentation and radiologic features of osteonecrosis with those of recurrent or progressive cancer. Methods: We conducted a single-center case series of 19 patients with head and neck squamous cell carcinoma diagnosed between 2011 and 2019 who subsequently developed clinical and/or radiological suspicion of osteoradionecrosis. The population was a referred sample from head and neck cancer physicians at Northwell Health Cancer Institute. Clinician notes and imaging reports were reviewed to assign a final diagnosis of either cancer, osteonecrosis, or indeterminate. Results: No differences were found in the clinical presentation or radiologic features between groups. Median time between treatment and development of symptoms was longer in patients with a final diagnosis of osteoradionecrosis than recurrent or progressive disease (5 vs. 3 months), but this difference was not statistically significant. Radiation dose and type were not associated with diagnosis. Mean standard uptake value maximums on positron emission tomography/computed tomography were significantly higher in the cancer group (median 14.8 vs. 9.1, p < 0.0152). At 1 year after first suspicion of osteoradionecrosis, 100% of osteoradionecrosis patients were alive, versus 28.6% of cancer patients. Discussion/Conclusion: There is significant overlap in clinical and radiologic features of osteoradionecrosis and cancer. Standard uptake maximums may be helpful in predicting diagnosis. Occurrence of symptoms within 6 months of completing chemoradiotherapy should raise the concern for malignancy.
- 1 December 2022
- Published by S. Karger AG in ORL
- Vol. 85 (1) , 28-35
Osteoradionecrosis versus Cancer Recurrence: An Unresolved Clinical Dilemma
Introduction: Osteoradionecrosis is a rare and debilitating risk of definitive chemoradiotherapy for head and neck squamous cell carcinoma. It is difficult to distinguish between osteoradionecrosis and recurrent or progressive disease, as clinical and radiologic features may be similar. Our aim was to compare the clinical presentation and radiologic features of osteonecrosis with those of recurrent or progressive cancer. Methods: We conducted a single-center case series of 19 patients with head and neck squamous cell carcinoma diagnosed between 2011 and 2019 who subsequently developed clinical and/or radiological suspicion of osteoradionecrosis. The population was a referred sample from head and neck cancer physicians at Northwell Health Cancer Institute. Clinician notes and imaging reports were reviewed to assign a final diagnosis of either cancer, osteonecrosis, or indeterminate. Results: No differences were found in the clinical presentation or radiologic features between groups. Median time between treatment and development of symptoms was longer in patients with a final diagnosis of osteoradionecrosis than recurrent or progressive disease (5 vs. 3 months), but this difference was not statistically significant. Radiation dose and type were not associated with diagnosis. Mean standard uptake value maximums on positron emission tomography/computed tomography were significantly higher in the cancer group (median 14.8 vs. 9.1, p < 0.0152). At 1 year after first suspicion of osteoradionecrosis, 100% of osteoradionecrosis patients were alive, versus 28.6% of cancer patients. Discussion/Conclusion: There is significant overlap in clinical and radiologic features of osteoradionecrosis and cancer. Standard uptake maximums may be helpful in predicting diagnosis. Occurrence of symptoms within 6 months of completing chemoradiotherapy should raise the concern for malignancy.
- Open Access
- 1 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 111 (3) , e424
Analysis of Toxicity and Local Control for Ultra-Central Lung Tumors Undergoing Stereotactic Body Radiation Therapy
- 1 November 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 111 (3) , e424
Open AccessAnalysis of Toxicity and Local Control for Ultra-Central Lung Tumors Undergoing Stereotactic Body Radiation Therapy
- 15 January 2021
- Published by Wiley in Head & Neck
- Vol. 43 (5) , 1428-1439
Dental radiation dosimetric maps from intensity‐modulated radiation therapy planning for head and neck cancers
Background: The purpose of this study was to create dental radiation maps to calculate the mean dose to individual teeth, maxilla and mandible using intensity‐modulated radiation therapy (IMRT).Methods: Eighteen common clinical settings were chosen. Radiation plans were extracted, and each tooth was contoured at its junction with the gingiva and labeled based on the Universal/American numbering system.Results: All patients were treated with prescribed doses of 50–70 Gy in 1.66–2 Gy/fraction. Patients receiving mean doses >50 Gy to the teeth, mandible, and maxilla included those with advanced tumors of the oral cavity and gross lymphadenopathy of level 1b.Conclusion: We believe this to be the first study generating dosimetric maps of estimated doses to each tooth and each third of the mandible and the maxilla for common examples of head and neck cancer faced by radiation oncologists. Adoption of these dental maps may help improve clinical workflow efficiency.
- 15 January 2021
- Published by Wiley in Head & Neck
- Vol. 43 (5) , 1428-1439
Dental radiation dosimetric maps from intensity‐modulated radiation therapy planning for head and neck cancers
Background: The purpose of this study was to create dental radiation maps to calculate the mean dose to individual teeth, maxilla and mandible using intensity‐modulated radiation therapy (IMRT).Methods: Eighteen common clinical settings were chosen. Radiation plans were extracted, and each tooth was contoured at its junction with the gingiva and labeled based on the Universal/American numbering system.Results: All patients were treated with prescribed doses of 50–70 Gy in 1.66–2 Gy/fraction. Patients receiving mean doses >50 Gy to the teeth, mandible, and maxilla included those with advanced tumors of the oral cavity and gross lymphadenopathy of level 1b.Conclusion: We believe this to be the first study generating dosimetric maps of estimated doses to each tooth and each third of the mandible and the maxilla for common examples of head and neck cancer faced by radiation oncologists. Adoption of these dental maps may help improve clinical workflow efficiency.
- Open Access
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (1) , 51-58
Computed tomography-based flap brachytherapy for non-melanoma skin cancers of the face
Purpose: Non-melanoma skin cancers of the face are at high-risk for local recurrence and metastatic spread. While surgical interventions such as Mohs microsurgery are considered the standard of care, this modality has the potential for high rates of toxicity in sensitive areas of the face. Catheter flap high-dose-rate (HDR) brachytherapy has shown promising results, with high rates of local control and acceptable cosmetic outcomes. Material and methods: Patients with non-melanoma skin cancers (NMSC) located on the face were treated with 40 Gy in 8 fractions, given twice weekly via catheter flap HDR brachytherapy. Clinical target volume (CTV) included the visible tumor plus a margin of 5 mm in all directions, with no additional planning target volume (PTV) margin. Results: Fifty patients with 53 lesions on the face were included, with a median follow-up of 15 months. All were considered high-risk based on NCCN guidelines. Median tumor size and thickness were 18 mm and 5 mm, respectively. Median PTV volume and D-90 were 1.7 cc and 92%, respectively. Estimated rate of local control at twelve months was 92%. Three patients (5%) experienced acute grade 2 toxicity. Two patients (4%) continued to suffer from chronic grade 1 skin toxicity at 12 months post-radiotherapy (RT), with an additional two patients (4%) experiencing chronic grade 2 skin toxicity. Forty-nine lesions (92%) were found to have a good or excellent cosmetic outcome with complete tumor remission. Conclusions: CT-based flap applicator brachytherapy is a valid treatment option for patients with NMSC of the face. This modality offers high rates of local control with acceptable cosmetic outcomes and low rates of toxicity.
- 1 January 2021
- Published by Termedia Sp. z.o.o. in Journal of Contemporary Brachytherapy
- Vol. 13 (1) , 51-58
Open AccessComputed tomography-based flap brachytherapy for non-melanoma skin cancers of the face
Purpose: Non-melanoma skin cancers of the face are at high-risk for local recurrence and metastatic spread. While surgical interventions such as Mohs microsurgery are considered the standard of care, this modality has the potential for high rates of toxicity in sensitive areas of the face. Catheter flap high-dose-rate (HDR) brachytherapy has shown promising results, with high rates of local control and acceptable cosmetic outcomes. Material and methods: Patients with non-melanoma skin cancers (NMSC) located on the face were treated with 40 Gy in 8 fractions, given twice weekly via catheter flap HDR brachytherapy. Clinical target volume (CTV) included the visible tumor plus a margin of 5 mm in all directions, with no additional planning target volume (PTV) margin. Results: Fifty patients with 53 lesions on the face were included, with a median follow-up of 15 months. All were considered high-risk based on NCCN guidelines. Median tumor size and thickness were 18 mm and 5 mm, respectively. Median PTV volume and D-90 were 1.7 cc and 92%, respectively. Estimated rate of local control at twelve months was 92%. Three patients (5%) experienced acute grade 2 toxicity. Two patients (4%) continued to suffer from chronic grade 1 skin toxicity at 12 months post-radiotherapy (RT), with an additional two patients (4%) experiencing chronic grade 2 skin toxicity. Forty-nine lesions (92%) were found to have a good or excellent cosmetic outcome with complete tumor remission. Conclusions: CT-based flap applicator brachytherapy is a valid treatment option for patients with NMSC of the face. This modality offers high rates of local control with acceptable cosmetic outcomes and low rates of toxicity.